Indivior Pharmaceuticals (FRA:E7P) Cyclically Adjusted Revenue per Share: €7.14 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:E7P Indivior Pharmaceuticals Inc FRA:E7P
71 GF Score
Price €32.80
GF Value €21.12
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is Indivior Pharmaceuticals Cyclically Adjusted Revenue per Share?

Indivior Pharmaceuticals FRA:E7P -1.20% 71 Cyclically Adjusted Revenue per Share is €7.14 as of Jun. 2026. GuruFocus rates FRA:E7P with a GF Score™ of 71/100 and a GF Value™ of €21.12 (Significantly Overvalued). The stock has 4 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Indivior Pharmaceuticals's adjusted revenue per share for the three months ended in Jun. 2026 was €2.401. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is €7.14 for the trailing ten years ended in Jun. 2026.

During the past 12 months, Indivior Pharmaceuticals's average Cyclically Adjusted Revenue Growth Rate was 4.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

As of today (2026-08-12), Indivior Pharmaceuticals's current stock price is €32.80. Indivior Pharmaceuticals's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2026 was €7.14. Indivior Pharmaceuticals's Cyclically Adjusted PS Ratio of today is 4.59.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Indivior Pharmaceuticals was 5.16. The lowest was 0.96. And the median was 2.50.


Indivior Pharmaceuticals  (FRA:E7P) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Indivior Pharmaceuticals's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=32.80/7.14
=4.59

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Indivior Pharmaceuticals was 5.16. The lowest was 0.96. And the median was 2.50.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Indivior Pharmaceuticals Cyclically Adjusted Revenue per Share Related Terms


Indivior Pharmaceuticals Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Indivior Pharmaceuticals's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Indivior Pharmaceuticals Cyclically Adjusted Revenue per Share Chart

Indivior Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 6.84 7.28 6.66

Indivior Pharmaceuticals Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6.35 6.65 6.66 6.92 7.14

FRA:E7P vs KNSA, AMRX, HIMS: Cyclically Adjusted Revenue per Share Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Indivior Pharmaceuticals's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Indivior Pharmaceuticals Cyclically Adjusted PS Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Indivior Pharmaceuticals's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Indivior Pharmaceuticals's Cyclically Adjusted PS Ratio falls into.


FRA:E7P
71GF Score
Indivior Pharmaceuticals Inc FRA:E7P
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Indivior Pharmaceuticals Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Indivior Pharmaceuticals's adjusted Revenue per Share data for the three months ended in Jun. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=2.401/333.9520*333.9520
=2.401

Current CPI (Jun. 2026) = 333.9520.

Indivior Pharmaceuticals Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201609 1.606 241.428 2.221
201612 1.652 241.432 2.285
201703 1.655 243.801 2.267
201706 1.712 244.955 2.334
201709 1.541 246.819 2.085
201712 1.497 246.524 2.028
201803 1.381 249.554 1.848
201806 1.529 251.989 2.026
201809 1.400 252.439 1.852
201812 1.380 251.233 1.834
201903 1.392 254.202 1.829
201906 1.258 256.143 1.640
201909 1.195 256.759 1.554
201912 0.795 256.974 1.033
202003 0.891 258.115 1.153
202006 0.861 257.797 1.115
202009 0.675 260.280 0.866
202012 0.998 260.474 1.280
202103 0.968 264.877 1.220
202106 1.069 271.696 1.314
202109 1.060 274.310 1.290
202112 1.316 278.802 1.576
202203 1.285 287.504 1.493
202206 1.420 296.311 1.600
202209 1.598 296.808 1.798
202212 1.681 296.797 1.891
202303 1.676 301.836 1.854
202306 1.785 305.109 1.954
202309 1.773 307.789 1.924
202312 1.974 306.746 2.149
202403 1.907 312.332 2.039
202406 2.058 314.175 2.188
202409 2.080 315.301 2.203
202412 2.189 315.605 2.316
202503 1.968 319.799 2.055
202506 2.078 322.561 2.151
202509 2.074 324.800 2.132
202512 2.334 324.054 2.405
202603 2.126 330.213 2.150
202606 2.401 333.952 2.401

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of €7.14 mean?
Indivior Pharmaceuticals (FRA:E7P) has a Cyclically Adjusted Revenue per Share of €7.14 as of Jun. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Indivior Pharmaceuticals and its competitors.
Is Indivior Pharmaceuticals' Cyclically Adjusted Revenue per Share too high?
Indivior Pharmaceuticals' current Cyclically Adjusted Revenue per Share is €7.14. Overall, Indivior Pharmaceuticals has a GF Score™ of 71/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Indivior Pharmaceuticals' Cyclically Adjusted Revenue per Share compare to KNSA and AMRX?
Indivior Pharmaceuticals' Cyclically Adjusted Revenue per Share of €7.14 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Drug Manufacturers company?
A good Cyclically Adjusted Revenue per Share depends on the Drug Manufacturers industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Indivior Pharmaceuticals and its competitors. Indivior Pharmaceuticals's current Cyclically Adjusted Revenue per Share is €7.14. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Indivior Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Indivior Pharmaceuticals (FRA:E7P) is currently considered Significantly Overvalued. The stock's GF Value™ is €21.12, compared to a current price of €32.80 — trading 55.3% above its estimated fair value. The current Cyclically Adjusted Revenue per Share is €7.14. Indivior Pharmaceuticals' overall GF Score™ is 71/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Indivior Pharmaceuticals (FRA:E7P), the current Cyclically Adjusted Revenue per Share is €7.14 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Indivior Pharmaceuticals (FRA:E7P) Overvalued in 2026?

Based on GuruFocus' analysis, Indivior Pharmaceuticals stock appears to be overvalued. The current stock price of €32.80 is trading 55.3% above its estimated GF Value™ of €21.12. GuruFocus considers Indivior Pharmaceuticals to be Significantly Overvalued.

Key valuation signals for FRA:E7P:

  • Cyclically Adjusted Revenue per Share: €7.14
  • GF Value™: €21.12 vs. price of €32.80 (55.3% above fair value)
  • GF Score™: 71/100 with 4 warning signs

No single metric tells the full story. See the FRA:E7P stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Indivior Pharmaceuticals Business Description

Other Exchanges INDV:USA
Address 10710 Midlothian Turnpike, Suite 125, North Chesterfield, Richmond, VA, USA, 23235
Indivior Pharmaceuticals Inc is a specialty pharmaceutical company singularly focused on delivering evidence-based treatment and advancing understanding of opioid use disorder (OUD) as a chronic but treatable brain disease. The company derives revenues from customers through the development, manufacture and sale of buprenorphine-based prescription drugs for treatment of opioid dependence and related disorders. The company's products include: Sublocade (buprenorphine extended-release monthly injection), and Suboxone (buprenorphine and naloxone sublingual film).
71GF Score

Get the complete analysis for FRA:E7P

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€32.80
Price
€21.12
GF Value